This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Fenofibrate on Sleep Apnea Syndrome

This study has been terminated.
(The study was prematurely terminated because of slow recruitment)
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: January 2, 2009
Last updated: July 17, 2009
Last verified: July 2009
Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.

Condition Intervention Phase
Dyslipidemia Sleep Apnea Syndrome Overweight Obesity Drug: Placebo Drug: Fenofibrate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome

Resource links provided by NLM:

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • Obstructive Apneas [ Time Frame: at one month of treatment ]
  • Desaturations [ Time Frame: at one month of treatment ]
  • Sleep Time With Oxygen Saturation Below 90% [ Time Frame: at one month of treatment ]
  • Apneas [ Time Frame: at one month of treatment ]
  • Hypopneas [ Time Frame: at one month of treatment ]
  • Index Apnea/Hypopnea [ Time Frame: at one month of treatment ]
  • Mixed Apneas [ Time Frame: at one month of treatment ]
  • Central Apneas [ Time Frame: at one month of treatment ]
  • Index of Apneas [ Time Frame: at one month of treatment ]
  • Index of Hypopneas [ Time Frame: at one month of treatment ]

Enrollment: 34
Study Start Date: September 2005
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Fenofibrate-matching placebo tablet
Drug: Placebo
Fenofibrate-matching placebo tablet
Experimental: 2
145 mg NanoCrystal fenofibrate tablet
Drug: Fenofibrate
145 mg NanoCrystal tablet


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea
  • Overweight or obese, with BMI >= 25 kg/m² and < 40 kg/m².
  • Known moderate hypertriglyceridemia, with fasting Triglycerides level >= 2.0 and < 6.0 mmol/L within 3 months before the inclusion.

Exclusion Criteria:

  • indication for immediate CPAP
  • other known endocrine disease, except treated and adequately controlled hypothyroidism
  • renal failure or plasma creatinine level >130 µmol/L
  • current chronic liver disease or ALanine Amino Transferase (ALT)> 2 times the upper normal limit (UNL)
  • symptomatic gallbladder disease
  • known muscular disease or creatine phosphokinase (CK) > 3 times UNL.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00816829

Site 1
Paris, France
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jean-Claude Ansquer, Solvay Pharmaceuticals Identifier: NCT00816829     History of Changes
Other Study ID Numbers: C LF178P 05 01
Study First Received: January 2, 2009
Results First Received: January 8, 2009
Last Updated: July 17, 2009

Keywords provided by Solvay Pharmaceuticals:
Sleep Apnea Syndromes
Overweight or obese patients

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Body Weight
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on August 23, 2017